W. L. Gore & Associates has purchased the assets and intellectual property of NMT Medical, including data related to CLOSURE I, for an undisclosed sum, while NMT was being auctioned off.
The CLOSURE I trial is a prospective, multicenter, randomized controlled trial of patent foramen ovale (PFO) closure with the StarFlex Device, compared with best medical therapy for the prevention of recurrent stroke and /or transient ischemic attack (TIA) in patients with cryptogenic stroke/TIA and PFO.
The study data were acquired with the rest of the NMT assets, but the transaction did not transfer any liabilities or regulatory obligations of NMT, according to the Newark, Del.-based Gore.
In early 2009, the StarFlex cardiac septal repair implant received FDA pre-market approval, enabling its commercial sale in the U.S. for patients with ventricular septal defects.
The acquisition came after NMT ceased operations earlier this year, Gore said, due to its need to liquidate assets.